Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Disease × alovudine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 3 Neoplasms 2 Central Nervous System Neoplasms 2 Carcinoma, Renal Cell 2 Breast Neoplasms 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Triple Negative Breast Neoplasms 1 Oligodendroglioma 1 Lung Neoplasms 1 Glioma 1 Glioblastoma 1 Ependymoma 1 Disease 1 Carcinoma, Non-Small-Cell Lung 1 Astrocytoma 1

Interventions

Dexamethasone 2 vistusertib 1 ricolinostat 1 pomalidomide 1 irinotecan sucrosofate 1 daratumumab 1 bermekimab 1 atezolizumab 1 alovudine 1 TKM-080301 1 TIC10 compound 1 Prostatectomy 1 Pluvicto 1 Magnetic Resonance Spectroscopy 1 Lenalidomide 1 Ipilimumab 1 Ga(III)-DOTATOC 1 Fluorouracil 1 Cyclophosphamide 1 Blood Specimen Collection 1 (225)Ac-PSMA-617 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00633958 2021-10-20

FLT

Dana-Farber Cancer Institute

Phase 1 Terminated

Disease, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡